Surging Prevalence of Chronic Diseases Driving Biosimilars Industry

In 2018, the global biosimilars market attained a value of $6.0 billion and is projected to register a 29.6% CAGR during the forecast period (2019–2024). The market is registering growth due to the inexpensive nature of biosimilar drugs, increasing geriatric population, rising research & development (R&D) investment by biopharmaceutical companies and extensive pipeline of biosimilars, and rising prevalence of chronic diseases. Generic equivalents of biologics are referred to as biosimilars. They are highly similar and comparable version of an approved biologic medicine and undergo clinical trials for demonstrating efficacy and safety. 

To learn more about this report: https://bit.ly/3hlqfwH

When technology is taken into consideration, the biosimilars market is divided into electrophoresis, monoclonal antibody (mAb), nuclear magnetic resonance, recombinant deoxyribonucleic acid, and bioassays. Out of these, the mAb technology dominated the market during the historical period 2014–2018 and is expected to account for the major share of the market during the forecast period as well. This is because of the increasing utilization of mAbs and technological advancements in the field. The division is further predicted to grow at the fastest pace during the forecast period.

Another major driving factor of the biosimilars market is the increasing R&D investment by biopharmaceutical companies and extensive pipeline of biosimilars. Pharmaceutical companies are considerably investing in their R&D processes, which is why several biopharmaceutical companies have biosimilars either in pipeline or are being marketed. For example, Teva Pharmaceuticals Industries Limited has two biosimilars in the pipeline, namely trastuzumab biosimilar, CT-P62 and rituximab injection, TRUXIMA. This indicates that companies are willingly investing in biologics, which is leading to the growth of the market. 

Geographically, Europe accounted for the major share of the biosimilars market during the historical period and is expected to contribute the largest revenue share to the market during the forecast period as well. This is attributed to the rising prevalence of chronic diseases, presence of established players, and growing geriatric population. Furthermore, partnerships and collaborations among the players in the region is predicted to create opportunities for the players in the market. North America is projected to advance at the fastest pace during the forecast period because of the rising number of product approvals.

Browse full report at: https://www.psmarketresearch.com/market-analysis/biosimilars-market

This Study Covers

• Historical and the present size of the biosimilars market

• Potential of on-demand logistics services, so the market players make informed decisions on the sales of their offerings

• Competitive scenario of various biosimilars market segments across key countries in several regions for uncovering market opportunities for the stakeholders

• Major players operating in the biosimilars market and their service offerings

• Recent strategic developments by the major players in the market